Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 17;15(5):e249684.
doi: 10.1136/bcr-2022-249684.

Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa

Affiliations
Case Reports

Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa

Sasank Konda et al. BMJ Case Rep. .

Abstract

A woman in her 30s presented to the dermatology clinic with widespread, pruritic, red papules and plaques involving the ears, trunk and extremities. The rash developed a few days after receiving her second injection of secukinumab, which was initiated for recalcitrant Hurley stage III hidradenitis suppurativa. Investigations revealed a psoriasiform drug hypersensitivity reaction secondary to secukinumab. In this report, we describe the clinical course, histopathological correlation and treatment of this rarely documented reaction.

Keywords: Dermatology; Hidradenitis suppurativa; Skin; Unwanted effects / adverse reactions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Visual timeline representing chronology of hypersensitivity reaction and prior medication use.
Figure 2
Figure 2
Clinical images of cutaneous delayed-type hypersensitivity (type IV) reaction to secukinumab. (A, B) Indurated, erythematous, scaly, crusted plaques with associated maceration on the bilateral axillary folds, as well as scattered erythematous papules and papulonodules on the abdomen and bilateral inframammary folds; taken 4 months after surgical excision of axillary hidradenitis suppurativa lesions and 6 weeks after initial onset of the eruption. (C, D) Resolution of the cutaneous hypersensitivity reaction 6 weeks after discontinuation of secukinumab and initiation of a prolonged prednisone taper.
Figure 3
Figure 3
Histological images of cutaneous delayed-type hypersensitivity (type IV) reaction to secukinumab. Low-power (A) and high-power views (B) showing regular epidermal hyperplasia with spongiosis and serous crusting with ample neutrophils in the stratum corneum, as well as a superficial perivascular and interstitial infiltrate of lymphocytes and numerous eosinophils. Periodic acid-Schiff stain was negative for fungal elements (not shown).

Similar articles

Cited by

References

    1. Casseres RG, Prussick L, Zancanaro P, et al. . Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 2020;82:1524–6. 10.1016/j.jaad.2020.02.005 - DOI - PubMed
    1. Gülsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int 2020;29:97–125. 10.1007/s40629-020-00126-6 - DOI - PMC - PubMed
    1. Shibata M, Sawada Y, Yamaguchi T, et al. . Drug eruption caused by secukinumab. Eur J Dermatol 2017;27:67–8. 10.1684/ejd.2016.2900 - DOI - PubMed
    1. Peigottu MF, Montesu MA. Adverse skin reaction to Secukinumab. J Eur Acad Dermatol Venereol 2017;31:e432–3. 10.1111/jdv.14248 - DOI - PubMed
    1. Wong SCT, Chung HY. Secukinumab-induced delayed-type drug hypersensitivity reactions. J Clin Rheumatol 2020;26:e197–8. 10.1097/RHU.0000000000001065 - DOI - PubMed

Publication types

Substances